Graft-versus-leukemia (GvL) effects and the success of allogeneic hematopoietic stem cell transplantation (HSCT) are based on the recognition of tumor-associated antigens (TAAs) presented to T cells via human leukocyte antigens (HLAs) [1,2,3]. Here, HLA-S is linked to neoplasm.